Cancer Drug Firm Duped Investors In $26M Offering: Suit

Law360, New York (February 3, 2012, 8:47 PM EST) -- Biopharmaceutical company GenVec Inc. raised $26.2 million from shareholders to develop a pancreatic cancer treatment it knew to be ineffective, according to a putative class action suit filed Friday in Maryland federal court.

Satish Shah launched the suit on behalf of investors in Gaithersburg, Md.-based GenVec, alleging the company artificially inflated its stock price through a series of misleading press releases before announcing in March 2010 that the treatment, TNFerade, had foundered during a pivotal clinical study called a PACT trial.

“Defendants knew or recklessly disregarded...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Shah v. Fischer et al


Case Number

8:12-cv-00341

Court

Maryland

Nature of Suit

Securities/Commodities

Judge

Deborah K. Chasanow

Date Filed

February 2, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.